Powered by

AgeneBio Announces Additional Funding to Advance Novel GABA-A Therapeutic Program to Address Alzheimer's and Other CNS Conditions; - AgeneBio has been awarded nearly $500,000 from the Alzheimer's Drug Discovery Foundation and has been selected to receive

Sep 11, 2019 - PR Newswire

PR Newswire

Building on previous progress in the NIH Blueprint Neurotherapeutics program, AgeneBio today announced it has received significant additional resources to accelerate the development of their GABA-A a5  Positive Allosteric Modulation (PAM), a novel approach to mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) that targets hippocampal overactivity that leads to degeneration and cognitive decline in patients with MCI due to AD, autism and schizophrenia.

In a challenging environment in the search for treatments related to Alzheimer's, AgeneBio's programs, including the pre-clinical GABA-A a5 and Phase-3 AGB-101, an investigational therapeutic currently being evaluated for its ability to treat MCI due to AD (NCT03486938), show great promise as novel approaches targeting overactivity in the brain. GABA-A a5 PAM targets hippocampal overactivity, which prior research suggests is a major contributor to cognitive decline in mild cognitive impairment (MCI) due to Alzheimer's Disease (AD). GABA-A a5 receptors are highly localized in the hippocampus making this an ideal target for addressing hippocampal overactivity. The AgeneBio discovery program is designed to enhance the activity of GABA at the GABA-A a5 receptor, which improves memory function in preclinical testing under conditions of hippocampal overactivity and aging. Proof of biology studies demonstrate that GABA-A a5 PAMs from multiple structural classes occupy GABA-A a5 receptors in the hippocampus and improve memory in preclinical studies of age-related cognitive impairment...